MHC class II on melanoma cells regulates the anti-tumor T cell response
The Journal of Immunology · 2026
DOI: 10.1093/jimmun/vkag158 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Immunology, 2026. Verfasst von Anne M Macy und 6 weiteren Autor:innen. Beteiligte Einrichtung: Phoenix Veterans Affairs Health Care System, Phoenix, AZ, United States. Hauptthemen laut MEDLINE: Histocompatibility Antigens Class II, Melanoma, CD8-Positive T-Lymphocytes, Skin Neoplasms. Die Arbeit nennt 53 Literaturangaben. Gefördert von: NIA NIH HHS, Institutes of Health, the University of Arizona College of Medicine Phoenix Springboard Initiative.
Abstract (Originalsprache)
In human melanoma, tumor cell-specific MHC class II expression is associated with improved response to programmed death 1 and programmed death-ligand 1 blockade; yet the direct effect of melanoma cell-specific MHC class II expression on anti-melanoma T cell responses remains largely unknown. In the clinically relevant Yale University Mouse Melanoma Exposed to Radiation (YUMMER) cell lines, MHC class II expression was IFN-γ-inducible in a subset of cells. Transduction of melanoma cells with CIITA resulted in uniformly high, constitutive expression of MHC class II. YUMMER.G cells transduced with CIITA vector had increased in vivo tumor growth in wild-type mice compared to melanoma cells transduced with empty vector. YUMMER.G cells transduced with empty or CIITA vectors had the same in vivo tumor growth in RAG−/− mice, indicating that the difference in tumor growth between CIITA- and empty-transduced cells was dependent on an intact adaptive immune system. CIITA-transduced YUMMER.G tumors exhibited an increased frequency and infiltration depth of CD4+ T cells, an increased frequency of T regulatory cells, and a decreased frequency and infiltration depth of CD8+ T cells, compared to empty-transduced tumors. Antibody depletion revealed that CIITA- and empty-transduced YUMMER.G tumors were constrained by CD4+ and CD8+ T cells, but only tumor growth of CIITA-transduced cells was decreased by CD25 blockade, which primarily blocks T regulatory cell function. Overall, this work reveals a potential pro-tumorigenic role of melanoma cell-specific overexpression of MHC class II.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Phoenix Veterans Affairs Health Care System, Phoenix, AZ, United States.
- Department of Dermatology, University of Arizona College of Medicine-Phoenix, Phoenix, AZ, United States.
- Department of Child Health, University of Arizona College of Medicine-Phoenix, Phoenix, AZ, United States.
- Division of Critical Care, Phoenix Children's Hospital, Phoenix, AZ, United States.
- Department of Immunology, Mayo Clinic, Phoenix, AZ, United States.
- Robert and Arlene Kogod Center on Aging, Mayo Clinic, Rochester, MN, United States.
ORCID-Profile: Anne M Macy, Jessica N Lancaster, Karen Taraszka Hastings
Förderung
- NIA NIH HHS
- Institutes of Health
- the University of Arizona College of Medicine Phoenix Springboard Initiative
- Biomedical Laboratory Research and Development Service Merit Review
- NCI NIH HHS
- Harry J. Lloyd Charitable Trust
- VA or the United States Government
- United States Department of Veterans Affairs (VA)
Zitieren
APA
Macy, A. M., Herrmann, L. M., Thornley, E. M., Adams, A. C., Stoll, C. R., Lancaster, J. N., & Hastings, K. T. (2026). MHC class II on melanoma cells regulates the anti-tumor T cell response. The Journal of Immunology. https://doi.org/10.1093/jimmun/vkag158
Vancouver
Macy AM, Herrmann LM, Thornley EM, Adams AC, Stoll CR, Lancaster JN, et al. MHC class II on melanoma cells regulates the anti-tumor T cell response. The Journal of Immunology. 2026. doi:10.1093/jimmun/vkag158
BibTeX
@article{Macy2026,
author = {Macy, Anne M and Herrmann, Lauren M and Thornley, Erin M and Adams, Anngela C and Stoll, Carly R and Lancaster, Jessica N and Hastings, Karen Taraszka},
title = {MHC class II on melanoma cells regulates the anti-tumor T cell response},
journal = {The Journal of Immunology},
year = {2026},
doi = {10.1093/jimmun/vkag158}
}
EUVIMED